Physician profile
Roy M Raynor
NPI 1396793477
$5,537.34
in general payments reported to CMS, 2019-2025
20 companies · $464 in 2025
The $464 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $544 · 2021: $802 · 2022: $851 · 2023: $997 · 2024: $832 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Entertainment: $98.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.86 |
| Entertainment | $98.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,279.56 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $1,055.87 | 2022-2025 | Infuse, Biotrue, Btod |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $653.11 | 2019-2021 | |
| Alcon Vision LLC | $480.70 | 2019-2025 | Total30, Tryptyr, Eysuvis |
| Johnson & Johnson Vision Care, INC. | $399.51 | 2019-2024 | Acuvue |
| Abbvie INC. | $285.19 | 2022-2025 | |
| Optos, INC. | $284.48 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $221.98 | 2019-2022 | |
| Oyster Point Pharma, INC. | $173.03 | 2022-2025 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $144.23 | 2019 | |
| Dompe US, INC. | $125.37 | 2022-2025 | Oxervate |
| Lkc Technologies, INC. | $112.25 | 2024 | |
| Maculogix, INC. | $107.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $80.69 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $50.04 | 2020-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $21.77 | 2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $18.99 | 2022 | |
| Topcon Healthcare, INC. | $14.69 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $14.36 | 2023 | Humphrey Hfa |
| Aerie Pharmaceuticals, INC. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Raynor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.